NEKTAR THERAPEUTICS (NKTR) — insider trading
Health Care · NASDAQ
NEKTAR THERAPEUTICS (NKTR) has 32 reported SEC Form 4 insider transactions in our data, including 14 open-market sales among the most recent 32 (latest 2026-09-23).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | WHITFIELD ROY A | Director | Grant / award / vesting (derivative) | 4,000 | — | $0 | Form 4 |
| 2026-09-23 | WHITFIELD ROY A | Director | Grant / award / vesting | 2,000 | — | $0 | Form 4 |
| 2026-09-23 | GREER R SCOTT | Director | Grant / award / vesting (derivative) | 4,000 | — | $0 | Form 4 |
| 2026-09-23 | GREER R SCOTT | Director | Grant / award / vesting | 2,000 | — | $0 | Form 4 |
| 2026-09-23 | CHESS ROBERT | Director | Grant / award / vesting (derivative) | 4,000 | — | $0 | Form 4 |
| 2026-09-23 | CHESS ROBERT | Director | Grant / award / vesting | 2,000 | — | $0 | Form 4 |
| 2026-09-23 | Brainard Diana | Director | Grant / award / vesting (derivative) | 4,000 | — | $0 | Form 4 |
| 2026-09-23 | Brainard Diana | Director | Grant / award / vesting | 2,000 | — | $0 | Form 4 |
| 2026-09-23 | Ajer Jeffrey Robert | Director | Grant / award / vesting (derivative) | 4,000 | — | $0 | Form 4 |
| 2026-09-23 | Ajer Jeffrey Robert | Director | Grant / award / vesting | 2,000 | — | $0 | Form 4 |
| 2026-08-18 | ROBIN HOWARD W | Director, Officer (President & CEO) | Open-market sale | 418 | $71.98 | $30.1K | Form 4 |
| 2026-08-18 | Zalevsky Jonathan | Officer (Chief R&D Officer) | Open-market sale | 186 | $71.98 | $13.4K | Form 4 |
| 2026-07-24 | ROBIN HOWARD W | Director, Officer (President & CEO) | Grant / award / vesting (derivative) | 57,200 | — | $0 | Form 4 |
| 2026-07-24 | Zalevsky Jonathan | Officer (Chief R&D Officer) | Grant / award / vesting (derivative) | 16,500 | — | $0 | Form 4 |
| 2026-06-30 | Zalevsky Jonathan | Officer (Chief R&D Officer) | Open-market sale | 5,681 | $70.00 | $397.7K | Form 4 |
| 2026-06-17 | ROBIN HOWARD W | Director, Officer (President & CEO) | Open-market sale | 4,500 | $61.65 | $277.4K | Form 4 |
| 2026-06-17 | ROBIN HOWARD W | Director, Officer (President & CEO) | Open-market sale | 5,500 | $60.81 | $334.5K | Form 4 |
| 2026-06-16 | ROBIN HOWARD W | Director, Officer (President & CEO) | Open-market sale | 4,697 | $60.71 | $285.2K | Form 4 |
| 2026-06-16 | ROBIN HOWARD W | Director, Officer (President & CEO) | Open-market sale | 5,303 | $59.97 | $318.0K | Form 4 |
| 2026-06-15 | Zalevsky Jonathan | Officer (Chief R&D Officer) | Open-market sale | 5,538 | $60.71 | $336.2K | Form 4 |
| 2026-05-19 | ROBIN HOWARD W | Director, Officer (President & CEO) | Open-market sale | 444 | $65.51 | $29.1K | Form 4 |
| 2026-05-19 | Zalevsky Jonathan | Officer (Chief R&D Officer) | Open-market sale | 199 | $65.51 | $13.0K | Form 4 |
| 2026-02-18 | ROBIN HOWARD W | Director, Officer (President & CEO) | Open-market sale | 423 | $73.00 | $30.9K | Form 4 |
| 2026-02-18 | Zalevsky Jonathan | Officer (Chief R&D Officer) | Open-market sale | 180 | $73.00 | $13.1K | Form 4 |
| 2026-01-20 | Zalevsky Jonathan | Officer (Chief R&D Officer) | Open-market sale | 3,867 | $35.67 | $137.9K | Form 4 |
| 2025-12-22 | ROBIN HOWARD W | Director, Officer (President & CEO) | Grant / award / vesting (derivative) | 86,667 | — | $0 | Form 4 |
| 2025-12-22 | ROBIN HOWARD W | Director, Officer (President & CEO) | Grant / award / vesting | 21,667 | — | $0 | Form 4 |
| 2025-12-22 | Zalevsky Jonathan | Officer (Chief R&D Officer) | Grant / award / vesting (derivative) | 25,000 | — | $0 | Form 4 |
| 2025-12-22 | Zalevsky Jonathan | Officer (Chief R&D Officer) | Grant / award / vesting | 6,250 | — | $0 | Form 4 |
| 2025-11-25 | Zalevsky Jonathan | Officer (Chief R&D Officer) | Open-market sale | 1,157 | $54.28 | $62.8K | Form 4 |
| 2025-11-21 | Zalevsky Jonathan | Officer (Chief R&D Officer) | Grant / award / vesting (derivative) | 4,766 | — | $0 | Form 4 |
| 2025-11-21 | Zalevsky Jonathan | Officer (Chief R&D Officer) | Grant / award / vesting | 2,666 | — | $0 | Form 4 |
Ask the chat about NKTR's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: NEKTAR THERAPEUTICS (NKTR).
Last updated 2026-09-23 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.